Treating Severe COVID-19 in Cancer Patients


The high fatality rate of COVID-19 pneumonia, especially in imuno-compromised high risk patient populations has triggered a global search for effective therapies that can stop or reverse the inflammatory process. This Cancer Reports and Reviews article, written by Fatih M. Uckun, MD, PhD, Vice President and Clinical Strategy Lead, Oncology and Hematology, summarizes the available risk mitigation strategies based on the insights and lessons learned from clinical trials in cancer patients in which a similar fulminant and systemic inflammatory process has been encountered.

Questions regarding your upcoming clinical trial?